Assessing in-vitro fertilisation at age 40 years.

Published in the Lancet.

In the four decades since the first birth by in-vitro fertilisation (IVF), the field has been rewarded with a Nobel prize, seen IVF evolve from an experimental procedure into clinical routine, and witnessed a pronounced shift in treatment utilisation from intrauterine inseminations to IVF. However, many studies have shown inferior newborn outcomes with IVF by comparison with spontaneously conceived pregnancies. These observed differences in infant outcomes have been suggested to be a bystander effect, reflective of underlying phenotypes of women who needed IVF to conceive. However, in these previous studies, researchers used random-effects models, focused only on children conceived by IVF, and included children conceived by other fertility treatments in control groups of natural conceptions. These design choices could bias results by underestimating the adverse effects of IVF.

Norbert Gleicher, MD, leads CHR’s clinical and research efforts as Medical Director and Chief Scientist. A world-renowned specialist in reproductive endocrinology, Dr. Gleicher has published hundreds of peer-reviewed papers and lectured globally while keeping an active clinical career focused on ovarian aging, immunological issues and other difficult cases of infertility.

Citation Page #: 393(10177):1181-1183.
Journal: Lancet
Author Publication: 429. Gleicher N, Barad DH.
Publication Link:
Date: 2019